Lantern Pharma is trading at $1.31, down 5.76%, as biotechnology stocks fall alongside higher Treasury yields, inflation concerns and weaker broader-market sentiment.
- No new company-specific announcement was identified for September 24, 2026. The latest highlighted items were a September 23 Open-Medicine AI webinar and a September 22 patent update.
- Shares have declined from $1.93 on September 16 to $1.31, extending recent weakness.